FindTrial
Sign In

Potency and requirement of propofol for loss of consciousness in end-stage renal disease patients.

Potency and requirement of propofol for loss of consciousness in end-stage renal disease patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003734
Enrollment
45
Registered
2019-04-10
Start date
2016-10-13
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Soon Chun Hyang University Hospital Seoul
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Aged = 20, American Society of Anestheisologists physical status I-II scheduled for elective surgery.

Exclusion criteria

Exclusion criteria: 1. Patients with neurological dysfuction, history of central nervous system disease, psychological disease 2. Patients on medications affecting central nervous system such as anticonvulsants, hypnotics, analgesics 3. Abnormal liver function 4. Body mass index (BMI) > 30 kg/m2 5. A history of adverse drug reaction with propofol and local anesthetics 6. A history of allergic reaxction with peanuts 7. A history of kidney transplantation

Design outcomes

Primary

MeasureTime frame
Potency and total amount of propofol for loss of consciousness are compared between end-stage renal disease patients and normal kidney function patients.—

Secondary

MeasureTime frame
Potency and total amount of propofol for loss of consciousness are compared between cervical epidural anesthesia with monitored anesthesia care and general anesthesia among end-stage renal disease patients.—

Countries

Korea, Republic of

Contacts

Public ContactMi Roung Jun

Soon Chun Hyang University Hospital Seoul

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026